Imanova acquired by Invicro to expand world-leading imaging services

The UK joint venture between the Medical Research Council (MRC) and top London universities has been acquired by US industry leader to create a global provider of imaging services and analytics across the entire drug development pipeline

After 6 years of successful growth and innovation, Imanova Limited has been acquired by Invicro LLC to establish a unique imaging and data management company, providing comprehensive services in support of drug development and disease research.

Founded in 2011 through a unique joint venture between the MRC, Imperial College London, Kings College London and University College London, Imanova is a world leader in the development of novel imaging biomarkers and analysis techniques and their application in clinical academic research and translational drug development.

Invicro’s acquisition of Imanova will secure over 90 high-tech jobs at the London imaging centre, and will provide substantial inward investment for UK science. Invicro will expand biomarker R&D and broaden the range of imaging services available from the London site by employing expertise in bio-analytics and data management.  Through this, Invicro will build on Imanova’s existing collaborations with UK academia.

“Strong support from the MRC and our academic partners has been critical to the successful development and expansion of imaging technology” – Kevin Cox, Imanova CEO, said – “this acquisition is a recognition of the excellence of UK science and will provide additional resource and expertise to drive innovation in imaging sciences for medical research and help reduce the risk, cost and time of drug development.”

Dr Jack Hoppin, Invicro CEO says, “Invicro is excited to invest in the UK, and Imanova is an ideal partner as the merger of our complementary capabilities will create a unique end-to-end imaging services and data management company that can effectively support our sponsors at all stages of the drug development life-cycle”.  

Previous acquisitions by Invicro include Molecular NeuroImaging LLC (MNI) in 2016, which added radioligand development and manufacturing, design and implementation of Phase I to Phase IV clinical trials, and customized clinical imaging site coordination and management in multi-site imaging studies.

About Invicro

Invicro, a leading global provider of imaging-based service solutions and image analysis software for research and drug development, was founded with a mission of improving the value of imaging in drug discovery and development. Invicro’s 250-person team provides a full range of imaging services and software solutions including contract imaging, research and clinical trial management services, custom data analysis, and software programs for image data management, visualization and high-throughput processing. For more information, visit www.invicro.com.

About Imanova

Imanova is a translational research company that specialises in applying positron emission tomography (PET) and magnetic resonance imaging (MRI) scanning techniques to improve productivity in early drug development and to help improve disease understanding.

Founded in 2011 through a unique joint venture between the MRC, Imperial College London, Kings College London and University College London, leveraging GSK technology know-how and early financial support, Imanova is today a world leader in the development of novel imaging biomarkers and analysis techniques and their application in clinical academic research and translational drug development, providing research collaboration to universities and industry in equal measure.

 

Archive